Spotlight on renin

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 2, 2005, Pages 107-109

  Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRORENIN; RENIN; RENIN INHIBITOR; ENZYME INHIBITOR;

ARTERIAL PRESSURE; ARTICLE; BLINDNESS; BLOOD PRESSURE REGULATION; BLOOD VOLUME; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY INJURY; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TREATMENT PLANNING; X RAY CRYSTALLOGRAPHY; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; KIDNEY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; KIDNEY; RENIN;

EID: 28244484426     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.008     Document Type: Article

References (31)

1. Skeggs LT, Kahn JR, Lentz KE, Shumway NP. Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53.
2. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
3. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
4. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta analysis: angiotensin receptor blockers in chronic heart failure and high risk acute myocardial analysis: angiotensin receptor blockers in chronic heart failure and high risk acute myocardial infarction. Ann Intern Med 2004;141:693-704.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
6. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
8. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997;349:1857-63.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:45-53.
10. Navar GL, Harrison-Bernard LM, Imig JD, Mitchell KD. Renal actions of angiotensin II and AT1 receptors. In: Angiotensin II Receptor Antagonists, edited by Epstein M, Brunner HR, Philadelphia, Hanley & Belfus, 2001, pp. 190.
11. Fisher NDL, Hollenberg NK. Renin Inhibition: What are the Therapeutic Opportunties. J Am Soc Nephrol 2005;16:592-9.
12. Fisher NDL, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs 2001;10:417-26.
13. Ondetti MA. Design of specific inhibitors of angiotensin converting enzyme: New class of orally active antihypertensive agents. Science 1977;196:441-4.
14. Kleinert HD, Stein HH. Specific renin inbibitors: Concepts and prospects. In: Hypertension, Pathophysiology, Diagnosis and Management, Vol. 2: Laragh JH, Brenner BM (eds), New York, Raven Press; 1995,pp.3065-77.
15. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002;39:e1-e8.
16. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1-7.
17. Skinner SL. The pathophysiology of prorenin. In: The Renin-Angiotensin System, edited by Ian J, Robertson S, Nicholls MG, New York, Gower Medical Publishing; 1993, pp.7.1-11.
18. Luetscher JA, Kraemer FB, Wilson DM. Prorenin and vascular complications of diabetes. Am J Hypertens 1989;2:382-6.
19. Yoshida H. A study on inactive renin in the plasma of patients with diabetes mellitus. Hokkaido Igaku Zasshi. Hokkaido J Med Sci 1989;64:232-42.
20. Franken AAM, Derkx FHM, Man in't Veld AJ et al. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 1990;71:1008-15.
21. Wilson D, Luetscher JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990;323:1101-06.
22. Danser AHJ, van den Dorpel MA, Deinum J et al. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endcrinol Metab 1989;68:160-7.
23. Deinum J, Derkx FHM, Danser AHJ, Schalekamp MADH. Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 1990;126:1673-82.
24. Derkx FHM. Human prorenin [Thesis], Rotterdam, Erasmus University of Rotterdam, 1987.
25. Misbin I, Grant MB, Pecker MS, Atlas SA. Elevated levels of plasma prorenin (inactive renin) in diabetic and nondiabetic patients with autonomic dysfunction. J Clin Endocrinol Metab 1987;64:964-8.
26. Wood JM, Stanton JL, Hofbauer KG. Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib 1987;1:169-85.
27. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996;50:1897-903.
28. Neutel JM, Luther RR, Boger RS, Weber MA. Immediate blood pressure effects of the renin inhibitor enalkiren and the ACE inhibitor enalaprilat. Am Heart J 1991;122:1094-100.
29. Kiowski W, Linder L, Kleinbloesem C, Van Brummelen P, Buhler FR. Blood pressure control of the renin-angiotensin system in normotensive subjects. Circulation 2002;85:1-8.
30. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition: Role of angiotensin II in humans. Hypertension 1994;23:44-51.
31. Fisher NDL, Hollenberg NK. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995;57:342-8.